Predictive factors for responding to sertraline treatment: Views from plasma catecholamine metabolites and serotonin transporter polymorphism

Journal of Psychopharmacology

Volumn 24, Issue 12, 2010, Pages 1764-1771

  Umene Nakano, Wakako ^a   Yoshimura, Reiji ^a   Ueda, Nobuhisa ^a   Suzuki, Akihito ^b   Ikenouchi Sugita, Atsuko ^a   Hori, Hikaru ^a   Otani, Koichi ^b   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

5 HTTLPR; BDNF; biological marker; depression; HVA; MHPG; sertraline

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOLAMINE; HOMOVANILLIC ACID; SEROTONIN TRANSPORTER; SERTRALINE;

ADULT; AGED; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HAMILTON SCALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, MAJOR; FEMALE; HOMOVANILLIC ACID; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650157200     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109106899     Document Type: Article

References (32)

1. Bolden-Watson C., Richelson E. (1993) Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52: 1023-1029.
2. Demyttenaere K., De Fruyt J., Stahl SM (2005) The many faces of fatigue in major depressive disorder. Int J Neuropsychop 8: 93-105.
3. Figurov A., Pozzo-Miller LD, Olafsson P., Wang T., Lu B. (1996) Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 381: 706-709.
4. Gelernter J., Kranzler H., Cubells JF (1997) Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet 101: 243-246.
5. Hamilton M. (1967) Development of a rating scale for primary depressive illness. Brit J Soc Clin Psyc 6: 278-296.
6. Heils A., Teufel A., Petri S., et al. (1996) Allelic variation of human serotonin transporter gene expression. J Neurochem 66: 2621-2624.
7. Hori H., Yoshimura R., Yamada Y., et al. (2007) Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharm 22: 21-27.
8. Kato M., Ikenaga Y., Wakeno M., et al. (2005) Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharm 20: 151-156.
9. Kirchheiner J., Nickchen K., Sasse J., Bauer M., Roots I., Brockmoller J. (2007) A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J 7: 48-55.
10. Kopin IJ (1985) Catecholamine metabolism: basic aspects and clinical significance. Pharmacolo Rev 37: 333-364.
11. Kunugi H., Hattori M., Kato T., et al. (1997) Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatr 2: 457-462.
12. Lesch KP, Bengel D., Heils A., et al. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531.
13. Mandrioli R., Saracino MA, Ferrari S., Berardi D., Kenndler E., Raggi MA (2006) HPLC analysis of the second-generation antidepressant sertraline and its main metabolite N-desmethylsertraline in human plasma. J Chromatogr. B, Analytical Technologies in the Biomedical and Life Sciences 836: 116-119.
14. Mauri MC, Fiorentini A., Cerveri G., et al. (2003) Long-term efficacy and therapeutic drug monitoring of sertraline in major depression. Human Psychopharmacology 18: 385-388.
15. Minegishi A., Ishizaki T. (1984) Determination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric detection. J Chromatogr 311: 51-57.
16. Montgomery SA, Asberg M. (1979) A new depression scale designed to be sensitive to change. Brit J Psychiat 134: 382-389.
17. Nagaoka S., Iwamoto N., Arai H. (1997) First-episode neuroleptic-free schizophrenics: concentrations with clinical response to haloperidol treatment. Biol Psychiat 41: 857-864.
18. Nutt DJ (2008) Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiat 69: 4-7.
19. Rapoport MJ, Chan F., Lanctot K., Herrmann M., McCullagh S., Feinstein A. (2008) An open-label study of citalopram for major depression following traumatic brain injury. J Psychopharmacol 22: 860-864.
20. Salamone JD, Correa M., Mingote S., Weber SM (2003) Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J Pharmacol Exp Ther 305: 1-8.
21. Schmitt JA, Ramaekers JG, Kruizinga MJ, van Boxtel MP, Vuurman EF, Riedel WJ (2002) Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. J Psychopharmacol 16: 207-214.
22. Sen S., Duman R., Sanacora G. (2008) Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiat.
23. Serretti A., Kato M., De Ronchi D., Kinoshita T. (2007) Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiat 12: 247-257.
24. Shinkai K., Yoshimura R., Ueda N., Okamoto K., Nakamura J. (2004) Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharm 24: 11-17.
25. Stahl SM (2008) Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (Essential Psychopharmacology Series), Third ed. Cambridge: Cambridge University Press.
26. Tatsumi M., Groshan K., Blakely RD, Richelson E. (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eu J Pharmacol 340: 249-258.
27. Ueda N., Yoshimura R., Shinkai K., Nakamura J. (2002) Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression. Pharmacopsychiatry 35: 175-181.
28. Yeung PK, Buckley SJ, Pedder SC, Dingemanse J. (1996) Determination of 3,4-dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid in human plasma by a simple and rapid high-performance liquid chromatography assay. J Pharm Sci 85: 451-453.
29. Yoshida K., Ito K., Sato K., et al. (2002) Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Progress in Neuropsychopharmacology and Biological Psychiatry 26: 383-386.
30. Yoshimura R., Mitoma M., Sugita A., et al. (2007) Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychoph 31: 1034-1037.
31. Yoshimura R., Nakamura J., Shinkai K., et al. (2004) Clinical response to antidepressants treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review. Prog Neuropsychoph 28: 611-616.
32. Yoshimura R., Nakamura J., Ueda N., Terao T. (2000) Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement. Int Clin Psychopharm 15: 175-180.